Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
07/2003
07/31/2003WO2003061728A2 Oral administration of interferon-tau
07/31/2003WO2003061710A1 AGENT CONTROLLING THE APOPTOSIS INDUCTION BY p73
07/31/2003WO2003061704A2 Combination therapy for the treatment of bacterial infections
07/31/2003WO2003061695A1 Methods of regulating cytokine receptor signaling
07/31/2003WO2003061691A1 Orodispersible pharmaceutical composition comprising perindopril
07/31/2003WO2003061690A1 Stimulation of bone growth and cartilage formation with thrombing peptide derivatives
07/31/2003WO2003061689A1 Thrombin derived peptides for promoting cardiac tissue repair
07/31/2003WO2003061688A1 Novel analgesics
07/31/2003WO2003061687A1 High-concentration preparation of soluble thrombomodulin
07/31/2003WO2003061686A1 Therapeutic application of g-csf, gm-csf and scf
07/31/2003WO2003061685A1 Therapeutic application of g-csf, gm-csf and scf
07/31/2003WO2003061684A2 Tumour treatment compositions comprising hsp70 and tumour necrosis factor
07/31/2003WO2003061683A1 Peptides for enhancing resistance to microbial infections
07/31/2003WO2003061682A1 The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus
07/31/2003WO2003061681A2 Proteins involved in the regulation of energy homeostasis and organelle metabolism
07/31/2003WO2003061680A2 Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of chronic obstructive pulmonary disease
07/31/2003WO2003061659A1 Treating stress response with chemokine receptor ccr5 modulators
07/31/2003WO2003061639A2 Use of glutathione synthesis stimulating compounds in reducing insulin resistance
07/31/2003WO2003061634A1 Sustained release pharmaceutical composition
07/31/2003WO2003061622A2 Method and device for feeding living cells into a biological body fluid
07/31/2003WO2003061602A2 Combination therapy for treatment of hiv infection
07/31/2003WO2003061592A2 Methods for therapeutic treatment of benign prostatic hypertrophy (bph)
07/31/2003WO2003061590A2 Peptide constructs for treating disease
07/31/2003WO2003061589A2 Methods for treating diseases or conditions with peptide constructs
07/31/2003WO2003061587A2 USE OF TGF-β ANTAGONISTS TO TREAT OR TO PREVENT CHRONIC TRANSPLANT REJECTION
07/31/2003WO2003061577A2 Polyalkylene glycol with moiety for conjugating biologically active compound
07/31/2003WO2003061573A2 Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 mo
07/31/2003WO2003061571A2 Combination il-2/anti-herz antibody therapy for cancers characterized by overexpression of the her2 receptor protein
07/31/2003WO2003061565A2 Use of calmodulin to promote bone regeneration
07/31/2003WO2003061564A2 Gene expression profiles in liver disease
07/31/2003WO2003061559A2 Binding peptides specific for the extracellular domain of erbb2 and uses therefor
07/31/2003WO2003061556A2 Ingestible capsaicin neutralizer
07/31/2003WO2003061386A1 Wt1 antisense oligos for the inhibition of breast cancer
07/31/2003WO2003061362A2 Methods and compositions for treating polycystic ovary syndrome
07/31/2003WO2003051345A3 Use of digestive enzyme mixtures for treating pathological bacterial overgrowth of the small intestine of mammals and humans
07/31/2003WO2003045978A3 Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment
07/31/2003WO2003040339A3 Antisense modulation of purinoreceptor p2x¿3?
07/31/2003WO2003037269A3 Di-, tri,- and tetra-peptides having antiangiogenic activity
07/31/2003WO2003037253A3 Methods for the treatment and diagnosis of tumorigenic and angiogenic disorders using 32616
07/31/2003WO2003035679A3 Molecules
07/31/2003WO2003031571A3 Novel human proteins, polynucleotides encoding them and methods of using the same
07/31/2003WO2003030720A3 Materials and methods for preventing or reducing scar formation
07/31/2003WO2003028636A3 Antisense modulation of il-1 receptor-associated kinase-4 expression
07/31/2003WO2003027246A3 Antagonists
07/31/2003WO2003026400A3 METABOTROPIC GLUTAMATE RECEPTOR 4B (mGluR4) DISRUPTIONS, COMPOSITIONS AND METHODS RELATING THERETO
07/31/2003WO2003025140A3 Transductin-1 and transductin-2 and applications to hereditary deafness
07/31/2003WO2003020702A9 Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
07/31/2003WO2003016333A3 Virus coat protein/receptor chimeras and methods of use
07/31/2003WO2003014702A3 Uses of mammalian cytokine; related reagents
07/31/2003WO2003011118A3 Human zona pellucida proteins and methods of their use in diagnosing male infertility
07/31/2003WO2003010139A3 Antisense modulation of hormone-sensitive lipase expression
07/31/2003WO2003008578A3 Reagents and methods for identifying gene targets for treating cancer
07/31/2003WO2003007867A3 A salt/ion pair medicinal aerosol formulation
07/31/2003WO2003004607A3 Aggrecanase molecules
07/31/2003WO2003002596A3 Use of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disorders
07/31/2003WO2002101005A3 A g-protein coupled receptor and uses therefor
07/31/2003WO2002098912A3 Guanylate-cyclase c ligand, administered via the airways, for the treatment of respiratory airway problems
07/31/2003WO2002098453A3 Orally administering parathyroid hormone and calcitonin
07/31/2003WO2002094202B1 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules
07/31/2003WO2002090571A3 Methods and compositions for modulating telomerase reverse transcriptase (tert) expression
07/31/2003WO2002090377A3 Peptides that bind to dna and inhibit dna replication, and methods of use
07/31/2003WO2002088363A3 Regulation of novel human prolyl 4-hydroxylases
07/31/2003WO2002086123A3 A human g-protein coupled receptor, hgprbmy11, expressed highly in heart and variants thereof
07/31/2003WO2002083729A3 Polypeptides derived from amyloid precursor peptide (app) and their uses
07/31/2003WO2002070707A3 Novel gpcr-like proteins and nucleic acids encoding same
07/31/2003WO2002064627A3 Crystallization of igf-1
07/31/2003WO2002063000A3 Purified and isolated platelet calcium channel nucleic acids and polypeptides and therapeutic and screening methods using same
07/31/2003WO2002062836A3 Detection of antibacterial activity in excretory secretory product of adult trichuris suis
07/31/2003WO2002060936A3 Vaccine and compositions for the prevention and treatment of neisserial infections
07/31/2003WO2002060464A3 Compositions containing an active fraction isolated from hedyotis diffusae and methods of use
07/31/2003WO2002059346A3 Constitutively active, hypersensitive, and nonfunctional receptors as novel therapeutic agents
07/31/2003WO2002058716A3 Treatment of inflammatory bowel disease using growth factors
07/31/2003WO2002047730A3 Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins
07/31/2003WO2002042458A3 G protein coupled receptors
07/31/2003WO2002039885A3 Compositions and methods for the therapy and diagnosis of ovarian cancer
07/31/2003WO2002038742A3 Dipeptidylpeptidases and methods of use
07/31/2003WO2002036732A9 Active variants of fgf with improved specificity
07/31/2003WO2002036169A3 Methods and compositions for enhanced delivery of bioactive molecules
07/31/2003WO2002029038A3 Novel proteins and nucleic acids encoding same and antibodies directed against these proteins
07/31/2003WO2002024909A3 Receptor nucleic acids and polypeptides
07/31/2003WO2002018548A3 Tyrosine hydroxylase 5' control elements and uses thereof
07/31/2003WO2002018444A3 Erbb4 antagonists
07/31/2003WO2002015895A3 Alpha-difluoromethylornithine (dfmo) use in the human prostate
07/31/2003WO2002012286A3 Stress proteins and peptides and methods of use thereof
07/31/2003WO2002004010A3 Inhibition of tumor growth by a nematode anticoagulant protein
07/31/2003WO2001098348A3 Regulation of cellproliferation and differentiation using topically applied peptides
07/31/2003WO2001095942A3 Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates
07/31/2003WO2001085912A3 Presenilin enhancers
07/31/2003US20030144727 Medical device for delivering biologically active material
07/31/2003US20030144497 Novel human transferase proteins and polynucleotides encoding the same
07/31/2003US20030144496 Isolated polypeptides; genetic engineering
07/31/2003US20030144495 Drosophila recombination-associated protein and methods for use
07/31/2003US20030144494 Using polypeptide; incubation, calibration drug
07/31/2003US20030144492 Anticancer agents; central nervous system disorders; antiinflammatory agents
07/31/2003US20030144491 Methods and materials relating to cadherin-like polypeptides and polynucleotides
07/31/2003US20030144486 Monoclonal human natural antibodies
07/31/2003US20030144485 Monoclonal human natural antibodies
07/31/2003US20030144484 Polynucleotides; immunoassay, immunotherapy
07/31/2003US20030144482 Diagnosis of skin cancer; vaccine
07/31/2003US20030144481 Controlling angiogenesis; controlling cell differentiation, proliferation
1 ... 1800 1801 1802 1803 1804 1805 1806 1807 1808 1809 1810 1811 1812 1813 1814 1815 1816 1817 1818 1819 1820 ... 3163